Direct acting antiviral therapy is curative for chronic hepatitis C/autoimmune hepatitis overlap syndrome

Sahebjam, Farhad; Hajdu, Cristina; Nortey, Esther; Sigal, Samuel H.

doi:10.4254/wjh.v8.i14.632

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to the current study, their conclusion was that normalization of serum markers of AIH after HCV eradication indicates that HCV was entirely responsible for the autoimmune response. Another report by Sahebjam et al reported similar findings.…”

Section: Discussionsupporting

confidence: 63%

“…Interferon (IFN)‐free or direct‐acting antiviral (DAA) therapies have provided major advances in the treatment of HCV, with greater than 90% of patients achieving sustained viral response (SVR) with most regimens, and have been shown to be safe and effective in patients with associated autoimmune conditions . The impact of DAA treatment on patients with HCV with elevated serum markers of AIH and transaminases, with or without the presence of histopathologic features of AIH, is not clear in the literature except for brief discussions in a few case reports . The goal of this study was to determine if the observed elevation of serum markers and histologic features of AIH in patients with HCV would normalize following DAA treatment.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis

et al. 2019

View full text Add to dashboard Cite

Patients with hepatitis C virus (HCV) often have elevated serum markers and histologic features of autoimmune hepatitis (AIH). We evaluated an HCV‐positive (HCV+) study group that had elevated serum markers of AIH before starting direct‐acting antiviral (DAA) therapy (n = 21) and compared them to an HCV+ control group that did not have laboratory studies suggesting AIH (n = 21). Several patients in the study (17/21) and control (11/21) groups had liver biopsies before DAA treatment, and many were biopsied due to elevated serum markers of AIH. Evaluation of pre‐DAA treatment liver biopsies showed histologic features suggestive of AIH in 64.7% (11/17) of the study group and 45.5% (5/11) of the control group. Patients who were HCV+ with elevated serum markers of AIH had significantly increased hepatitis activity (P < 0.001) and slightly increased fibrosis stages (P = 0.039) in their pretreatment liver biopsies compared to controls. We hypothesized that the elevated serum markers and histologic features of AIH would resolve following DAA treatment. Serum markers of AIH in the study group began decreasing by 6 months posttreatment, and 52.4% (11/21) had complete resolution. Alanine aminotransferase levels significantly decreased into the normal range for all patients (21/21). Even patients that had persistence of serum markers of AIH after DAA treatment had normal transaminases. Six patients from the study patient group and 4 patients from the control group had follow‐up liver biopsies after DAA treatment, and all biopsies showed resolution of the histologic features of AIH. Conclusion: The majority of HCV+ patients that have serum markers and/or histopathologic features of AIH should initially be treated with DAA.

show abstract

Section: Discussionsupporting

confidence: 63%

mentioning

confidence: 99%

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Слабость, артралгия АИГ [11][12][13]. Вместе с тем описаны случаи дебюта АИГистинного и лекарственно-индуцированного -во время и после лечения препаратами прямого действия [14][15][16].…”

Section: рис 2 п 1985 гр хронический гепатит с Hcv рнк 1bunclassified

Cross-syndrome of Chronic Hepatitis C and Type 1 Autoimmune Hepatitis with Subsequent Transformation into Type 2 Autoimmune Hepatitis: a Clinical Case

Buyeverov¹,

Roschina²,

Kuzmina³

et al. 2022

EPh

View full text Add to dashboard Cite

We present clinical case of patient with initially diagnosed chronic hepatitis C with an autoimmune component corresponding to type 1 autoimmune hepatitis. Considering that at the time of diagnosis, the therapeutic possibilities of hepatitis C were limited to the use of standard or pegylated interferon α in combination with ribavirin, in order to avoid the adverse immunomodulatory effect of interferon, we previously suppressed the autoimmune component with immunosuppressors. After 6-month course of prednisolone and azathioprine, antiviral therapy with interferon α and ribavirin was carried out with the achievement of sustained virological and biochemical response. After 7 years of complete virological, immunological and biochemical remission, the patient manifested autoimmune hepatitis type 2. The appointment of prednisolone and azathioprine led to a stable drug-induced remission.

show abstract

Histological improvement in chronic hepatitis C-autoimmune hepatitis overlap syndrome by glecaprevir and pibrentasvir

Matsumoto

Kikuchi

Namura

et al. 2023

Clin J Gastroenterol

View full text Add to dashboard Cite

Direct acting antiviral therapy is curative for chronic hepatitis C/autoimmune hepatitis overlap syndrome

Cited by 4 publications

References 15 publications

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis

Cross-syndrome of Chronic Hepatitis C and Type 1 Autoimmune Hepatitis with Subsequent Transformation into Type 2 Autoimmune Hepatitis: a Clinical Case

Histological improvement in chronic hepatitis C-autoimmune hepatitis overlap syndrome by glecaprevir and pibrentasvir

Contact Info

Product

Resources

About